Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 19, 2014, 71 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $119.85 to $228,846,700.60.

Highlighted Stocks Traded by Insiders:

HD Supply Holdings (HDS) - FREE Research Report

Berges James G, who is Director at HD Supply Holdings, bought 35,350 shares at $28.23 on Dec. 19, 2014. Following this transaction, the Director owned 35,350 shares meaning that the stake was boosted by 100% with the 35,350-share transaction.

McNamee Patrick, who is Director at HD Supply Holdings, bought 7,500 shares at $27.27 on Dec. 19, 2014. Following this transaction, the Director owned 10,596 shares meaning that the stake was boosted by 242.25% with the 7,500-share transaction.

The shares most recently traded at $29.28, up $2.01, or 6.88% since the insider transaction. Historical insider transactions for HD Supply Holdings go as follows:

  • 4-Week # shares sold: 40,000
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 40,000
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 40,000

The average volume for HD Supply Holdings has been 1.7 million shares per day over the past 30 days. HD Supply Holdings has a market cap of $5.4 billion and is part of the services sector and wholesale industry. Shares are up 14.29% year-to-date as of the close of trading on Thursday.

HD Supply Holdings, Inc. operates as an industrial distribution company in North America. It operates in four segments: Facilities Maintenance, Waterworks, Power Solutions, and Construction & Industrial - White Cap. The company has a P/E ratio of 114.3. Currently, there are 11 analysts who rate HD Supply Holdings a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HDS - FREE

TheStreet Quant Ratings

rates HD Supply Holdings as a

sell

. Among the areas we feel are negative, one of the most important has been poor profit margins. Get the full

HD Supply Holdings Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

SL Green Realty (SLG) - FREE Research Report

Mead James E, who is Chief Financial Officer at SL Green Realty, sold 6,731 shares at $120.03 on Dec. 19, 2014. Following this transaction, the Chief Financial Officer owned 23,438 shares meaning that the stake was reduced by 22.31% with the 6,731-share transaction.

The shares most recently traded at $121.78, up $1.75, or 1.44% since the insider transaction. Historical insider transactions for SL Green Realty go as follows:

  • 4-Week # shares sold: 95,439
  • 12-Week # shares sold: 95,439
  • 24-Week # shares sold: 95,439

The average volume for SL Green Realty has been 782,700 shares per day over the past 30 days. SL Green Realty has a market cap of $11.8 billion and is part of the financial sector and real estate industry. Shares are up 33.25% year-to-date as of the close of trading on Thursday.

SL Green Realty Corp. is a real estate investment trust (REIT). The firm engages in the property management, acquisitions, financing, development, construction, and leasing. It also provides tenant services to its clients. The firm invests in real estate markets of the United States. The stock currently has a dividend yield of 1.96%. The company has a P/E ratio of 25.3. Currently, there are 6 analysts who rate SL Green Realty a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SLG - FREE

TheStreet Quant Ratings

rates SL Green Realty as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full

SL Green Realty Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

NxStage Medical (NXTM) - FREE Research Report

Swan Winifred L, who is SVP and General Counsel at NxStage Medical, sold 500 shares at $18.25 on Dec. 19, 2014. Following this transaction, the SVP and General Counsel owned 18,688 shares meaning that the stake was reduced by 2.61% with the 500-share transaction.

The shares most recently traded at $18.09, down $0.16, or 0.88% since the insider transaction. Historical insider transactions for NxStage Medical go as follows:

  • 4-Week # shares bought: 10,150
  • 4-Week # shares sold: 10,500
  • 12-Week # shares bought: 10,150
  • 12-Week # shares sold: 31,316
  • 24-Week # shares bought: 10,150
  • 24-Week # shares sold: 52,311

The average volume for NxStage Medical has been 423,300 shares per day over the past 30 days. NxStage Medical has a market cap of $1.1 billion and is part of the health care sector and health services industry. Shares are up 80.35% year-to-date as of the close of trading on Thursday.

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Currently, there are 4 analysts who rate NxStage Medical a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on NXTM - FREE

TheStreet Quant Ratings

rates NxStage Medical as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full

NxStage Medical Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null